KRTX News and Press, Karuna Therapeutics Inc. From 09/09/22

Summary Karuna Therapeutics could disrupt the Schizophrenia market with its differentiated drug candidate KarXT. The drug has unique properties and has demonstrated outstanding efficacy in Phase 2 and 3 trials. Provided Karuna obtains some additional safety data demanded by th...

Summary Karuna produced excellent data from its phase 3 trial. They have a boatload of cash. Speaking of boats, however, this ship has already sailed. Since my last coverage of Karuna Therapeutics, Inc. ( KRTX ) just over a year back, the stock has nearly tri...

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that senior management will present at the following upcoming invest...

The following slide deck was published by Karuna Therapeutics, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Karuna Therapeutics, Inc. 2022 Q2 - Results - Earnings Call Presentation

Clinical-stage biopharmaceutical company Karuna Therapeutics ( NASDAQ: KRTX ) closed a previously-announced upsized underwritten public offering of ~4M shares, with the underwriters exercising in full their option to purchase an additional 523K shares at $215 per share. ...

Karuna Therapeutics, Inc. (NASDAQ: KRTX) (“Karuna”), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced the closing of its previously announced ups...

Karuna Therapeutics ( NASDAQ: KRTX ) has priced an upsized underwritten public offering of 3,488,373 shares of its common stock at a public offering price of $215.00 per share for expected gross proceeds to be ~$750.0M. Offering is expected to close on or about August 12, ...

The major U.S. equity averages finished Monday's session with a mixed performance, continuing the uncertainty that marked most of last week. Weakness in semiconductor stocks weighed on the market. Breaking out of the lackluster trading, a handful of high-profile meme stocks showed notab...

Karuna Therapeutics ( NASDAQ: KRTX ) on Monday announced a $600M underwritten stock offering . KRTX intends to grant underwriters a 30-day option to buy an additional $90M of its stock in the offering. There can be no assurance as to whether or when the offering may be...

Karuna Therapeutics (NASDAQ: KRTX) , a clinical-stage biotech , is having a record-breaking day. As of 2:25 p.m. ET, the company's shares were up by an eye-popping 70%, surging to an all-time high during Monday's trading session. Although the biotech released its 2022 second...